Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Multicentre Phase II Study of the Efficacy and Safety of Lenalidomide in High-risk Myeloid Disease (High-risk MDS and AML) With a Karyotype Including Del(5q) or Monosomy 5

NCT00761449 is registered in ClinicalTrials.gov with Nordic MDS Group as lead sponsor.

NCT NCT00761449
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00761449 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Multicentre Phase II Study of the Efficacy and Safety of Lenalidomide in High-risk Myeloid Disease (High-risk MDS and AML) With a Karyotype Including Del(5q) or Monosomy 5
Lead sponsor
Nordic MDS Group
Phase
Phase 2
Overall status
Completed
Start date
October 31, 2007
Completion date
December 31, 2009
Enrollment
28 (actual)
Sites
18

Conditions

As the registry lists them; a condition with its own page is linked.

aml, mds